Data study · Published August 3, 2026 · figures verified July 31, 2026
The Real All-In Cost of a GLP-1 in 2026
We pulled every 2026 way to pay for a GLP-1 in the US into one dated, primary-sourced picture. The short version: the same medication ranges from about $25 to about $1,349 a month, and the number a telehealth ad shows you is rarely the number you actually pay.
Educational synthesis of public data — not original research, not a price quote, and not medical or financial advice. Every figure links to its primary source and should be re-verified on the day you buy. To compute your own number, use our all-in cost calculator.
Key findings
≈ 54×
spread on the same medicine
The identical GLP-1 can cost from about $25/month to about $1,349/month — a roughly 54× swing driven entirely by how you access it, not by the drug itself.
≈ 74%
below list, direct from the maker
Manufacturer-direct cash prices (~$349/mo) now run about 74% below the brand-name list price (~$1,349/mo) — a route that only became broadly available across 2025–2026.
18 months
until the cheapest path expires
Medicare’s $50/month Bridge is a demonstration running July 1, 2026 → December 31, 2027 — roughly 18 months. It is not permanent coverage, and the $50 sits outside the Part D benefit.
Apr 30, 2026
the day the cheapest sticker started disappearing
The lowest historical price — compounded GLP-1s — is being regulated out. On April 30, 2026 the FDA proposed permanently ending bulk compounding of semaglutide, tirzepatide, and liraglutide.
What each path costs per month (2026)
Representative US monthly costs by access path. Bars scaled to the brand-name list price ($1,349). Ranges reflect dose and program differences — see notes and sources.
Eligible beneficiaries · time-limited demo, expires Dec 31, 2027
Cheapest when covered — but weight-loss coverage is the hard part
Often promotional; confirm the price for your maintenance dose
Historically the cheapest sticker — now being restricted; not FDA-approved
Injectables launched ~$350, stated path toward ~$245 over ~2 years
NovoCare (Wegovy ~$349) · LillyDirect (Zepbound $299–449 by dose)
No insurance, no program — the number on the sticker
Sources: CMS (Medicare Bridge), FDA (oral Wegovy approval; compounding proposal), Lilly and NovoCare (official self-pay pages), KFF, and TrumpRx.gov. Full links below. Prices change monthly.
Why the “all-in” number is the one that matters
The single most common way people overpay is reading a membership price as if it were the total price. A telehealth ad that says “from $99/month” often means the program fee only — the medication, labs, and shipping are extra. Here is an illustrative build-up (figures vary by provider and dose; this is an example, not a quote):
| Line item | Illustrative monthly |
|---|---|
| Advertised membership | $99 |
| Medication (not included above) | ~$199 |
| Labs + consult (amortized) | ~$25 |
| Shipping | ~$10 |
| Real all-in | ~$333 |
In this example the advertised figure covered under a third of the true cost. The fix is simple and works every time: get the all-in number — drug + visits + labs + fees — in writing before you commit. Our cost calculator does that build-up for you, and the 2026 price tracker keeps the underlying figures current.
Methodology & honest limitations
- • What this is: a synthesis of publicly available, primary-source 2026 US pricing — FDA approvals, CMS program terms, and manufacturers’ own published self-pay prices — aggregated into one dated place.
- • What this is not: original research. We did not survey patients or pharmacies, and we do not hold a proprietary dataset. It is also not medical or financial advice, and not a price quote.
- • Figures: representative monthly costs; ranges reflect dose and program differences. Insurance-copay and compounded ranges are typical published patterns, not fixed prices.
- • Currency: this market re-prices monthly. Figures were verified July 31, 2026; the official source on the day you buy is what governs your cost.
Citing this study?
You’re welcome to reference these figures. Please link to the study and credit Well Basecamp so readers can check the sources and see the verification date.
Writing a piece and want the underlying per-dose figures or the chart? Reach us at our contact page.
Find your real number in seconds
Add up membership, medication, labs, and shipping — then see which provider path fits your budget.
Sources (primary / authoritative)
- CMS — Medicare GLP-1 Bridge program ($50/month)
- FDA — proposed 503B bulks-list exclusion of GLP-1s (Apr 30, 2026)
- Novo Nordisk — FDA approves oral Wegovy (Dec 2025)
- Lilly — Zepbound self-pay pricing (official)
- NovoCare — Wegovy self-pay (official)
- KFF — Medicare/Medicaid GLP-1 coverage explainer
Prices and programs in this category change monthly. This page is educational, not medical or financial advice, and not a price quote. Some pages we link to elsewhere on this site contain affiliate links; see our affiliate disclosure.